Related Experiment Video
Updated: Mar 2, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
904
Novel agents in mantle cell lymphoma.
1a Department of Haematology , Derriford Hospital , Plymouth , UK.
Expert Review of Anticancer Therapy
|May 9, 2017
Summary
Novel targeted therapies have transformed mantle cell lymphoma (MCL) treatment, offering new hope for patients with this aggressive cancer. Research highlights licensed and emerging agents, including Bruton
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a historically poor prognosis.
- Recent advancements in targeted therapies have significantly improved treatment options for MCL.
- Novel agents target specific intracellular pathways and the tumor microenvironment.
Purpose of the Study:
- To summarize licensed novel agents for front-line and relapsed/refractory MCL treatment.
- To discuss promising targeted therapies in earlier stages of development.
- To provide an expert commentary on the evolving landscape of MCL therapeutics.
Main Methods:
- Literature search using terms like 'mantle cell lymphoma', 'bortezomib', 'ibrutinib', and 'targeted molecular therapies'.
- Review of current literature on licensed and investigational agents for MCL.
- Synthesis of findings to provide an expert perspective.
Main Results:
- Novel molecular targets and drugs have revolutionized MCL therapy beyond traditional immunochemotherapy.
- Targeted agents, including Bruton's tyrosine kinase inhibitors, represent a significant breakthrough.
- Several novel agents are now licensed for MCL treatment in various settings.
Conclusions:
- Targeted therapies have transformed MCL treatment, improving outcomes for patients.
- Optimizing the sequencing and combination of these agents presents new challenges.
- Overcoming drug resistance is a critical area for future research in MCL.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:16Primary Lymphoid Organs
16.2K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.2K
01:15Differentiation of Common Myeloid Progenitor Cells
4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
01:18Lymphoid Cells and Tissues
3.5K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.5K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K